Clinical characteristics and corticosteroids application of different clinical types in patients with corona virus disease 2019

Fangfang Liu1,7, Chengcheng Ji1,7, Jiajun Luo2, Weiwei Wu3, Junchang Zhang1, Zhiquang Zhong1, Seth Lankford4, Huang Huang2, Fang Lin1, Yonggang Wang2, Guoxin Mo5, Xingshuo Hu5, Tianjun Jiang1, Yanling Shao1, Sumin Ji1, Yawei Zhang2,6, Enqiang Qin1,5, & Jinsong Mu1*

To describe the epidemiological and clinical characteristics of patients with Corona Virus Disease 2019 (COVID-19) in Beijing. To analyze the application of corticosteroids in patients with severe pneumonia. We collected information on demographic characteristics, exposure history, clinical characteristics, corticosteroids use, and outcomes of the 65 confirmed cases of COVID-19 at Fifth Medical Center of PLA General Hospital from Jan 20 to Feb 23, 2020. The final follow-up date observed was April 15th, 2020. The number of patients with mild, general, severe, and critical type were 10 (15.38%), 32 (49.23%), 8 (12.31%), and 15 (23.08%), respectively. The median incubation period was 6 days. Notable outliers were 1 patient at 16 days and 1 patient at 21 days. In lymphocyte subgroup analysis, decreases in total, T, CD4, and CD8 lymphocytes were more common as the disease worsened (All \( P < 0.05 \)). Methylprednisolone (mPSL) was applied to 31 (47.69%) patients with pneumonia, including 10 (31.25%) general, 8 (100%) severe, and 13 (86.67%) critical patients, respectively. Corticosteroids inhibited Interleukin-6 (IL-6) production (\( P = 0.0215 \)) but did not affect T lymphocyte (\( P = 0.0796 \)). There was no significant difference between patients using lower dose (≤ 2 mg/kg day) and higher dose (> 2 mg/kg day) mPSL in inhibiting IL-6 production (\( P = 0.5856 \)). Thirty of 31 patients (96.77%) had stopped mPSL due to improvement of pneumonia. Virus RNA clearance time lengthened with disease progression (\( P = 0.0001 \)). In general type, there was no significant difference in virus clearance time between patients with (15, 12–19 days) and without (14.5, 11–18 days) (\( P = 0.7372 \)) mPSL use. Lymphocyte, especially T lymphocyte, in severe and critical patients showed a dramatic decrease. Application of lower dose corticosteroids (≤ 2 mg/kg day) could inhibit IL-6 production (a representative of cytokines) as effectively as a higher dose. Proper use corticosteroids in general type patients did not delay virus clearance.

In December 2019, cases of acute respiratory disease (ARD), now known as a Corona Virus Disease 2019 (COVID-19) occurred in Wuhan, Hubei Province, China1–3. Presently, the laboratory-confirmed cases and recorded deaths in the world are still increasing at an alarming rate4–10.

COVID-19 clinical types were defined according to the Diagnosis and Treatment of Pneumonia caused by Novel Coronavirus (Version 6 Trial) published on the website of the Central Government of the People's Republic of China11. There are four distinct clinical types based on the severity of the disease. However, the differences in clinical characteristics, corticosteroids application, and outcomes among different clinical types have not been reported.

1Fifth Medical Center of PLA General Hospital, Beijing, China. 2Department of Environmental Health Sciences, Yale School of Public Health, Yale University, New Haven, CT, USA. 3Shanxi Medical University, Taiyuan, Shanxi, China. 4Duke University, Durham, NC, USA. 5First Medical Center of PLA General Hospital, Beijing, China. 6Department of Surgery, Yale School of Medicine, Yale University, New Haven, CT, USA. 7These authors contributed equally: Fangfang Liu and Chengcheng Ji. *email: yawei.zhang@yale.edu; qeq2004@sina.com; jinsongmu302@163.com
The pathophysiology of COVID-19 includes severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binding to the alveolar epithelium, activating innate immune system and adaptive immune system, resulting in a pro-inflammatory cascade, including the release of Interleukin 6 (IL-6) \(^1\). Corticosteroid treatment can suppress inflammation, and was used frequently for treatment of patients with severe illness to reduce lung inflammation\(^1\)\(^-\)\(^4\). Corticosteroids were widely used during the outbreaks of severe acute respiratory syndrome (SARS)-CoV and Middle East respiratory syndrome (MERS)-CoV, and are being used in patients with COVID-19\(^1\),\(^5\),\(^6\). In light of the urgent clinical demand, physicians from the Chinese Thoracic Society who participated in treating patients with 2019-nCoV pneumonia have developed an expert consensus statement on the use of corticosteroids in COVID-19\(^7\),\(^8\). The outcomes of patients with different COVID-19 clinical types treated by corticosteroids have not been reported.

The aim of the study is to compare clinical characteristics and outcomes among different clinical types of COVID-19 patients treated in a tertiary hospital in Beijing, and to analyze the application of corticosteroids in patients with severe pneumonia.

### Methods

#### Data collection.

All laboratory-confirmed patients admitted to Fifth Medical Center of PLA General Hospital from January 20 to February 23, 2020, were enrolled. Cases were diagnosed based on Diagnosis and Treatment of Pneumonia caused by Novel Coronavirus (Version 6 Trial) published on the website of the Central Government of the People’s Republic of China\(^1\). A confirmed case of COVID-19 was defined as a positive result from real-time reverse-transcriptase polymerase-chain-reaction (RT-PCR) assay of respiratory tract specimens\(^7\),\(^8\). Medical records of all confirmed cases with COVID-19 were obtained from electronic medical records. The clinical outcomes, including discharges, mechanical ventilation, intensive care unit (ICU) admission, and death, were recorded up to April 15th, 2020, the final follow-up date for this study.

### Table 1. Demographics and baseline characteristics of 65 patients admitted to the 5th Medical Center of PLA General Hospital (Jan 20–Feb 23, 2020) with COVID-19 in different clinical types. COVID-19 Corona Virus Disease 2019, ICU intensive care unit, IQR interquartile range, HFNC high-flow nasal cannula, NIPPV non-invasive positive pressure ventilation, IPPV invasive positive pressure ventilation, Med Median.

| Variables | Total (n = 65) | Mild (n = 10) | General (n = 32) | Severe (n = 8) | Critical (n = 15) |
|-----------|---------------|---------------|-----------------|---------------|------------------|
| Age, years | N % | N % | N % | N % | N % | N % |
| ≤ 65 | 50 76.92 | 10 10.00 | 29 90.63 | 5 62.50 | 6 40.00 |
| > 65 | 15 23.08 | 0 0.00 | 3 9.38 | 3 37.50 | 9 60.00 |
| Sex | N % | N % |
| Male | 36 55.38 | 6 60.00 | 18 56.25 | 4 50.00 | 8 53.33 |
| Female | 29 44.62 | 4 40.00 | 14 43.75 | 4 50.00 | 7 46.67 |
| Exposure history | N % | N % | N % | N % | N % |
| No exposure history | 7 10.77 | 0 0.00 | 1 3.13 | 0 0.00 | 6 40.00 |
| Recently been to Wuhan | 36 55.38 | 8 80.00 | 20 62.50 | 3 37.50 | 5 33.33 |
| Contacted with patients with COVID-19 | 17 26.15 | 0 0.00 | 10 31.25 | 5 62.50 | 2 13.33 |
| Contacted with people from Wuhan | 5 7.69 | 2 20.00 | 1 3.13 | 0 0.00 | 3 20.00 |
| With at least one underlying disease | 22 33.85 | 1 10.00 | 8 25.00 | 4 50.00 | 9 60.00 |
| Treatment | N % | N % | N % | N % | N % |
| Respiratory support | N | N | N | N | N |
| Oxygen therapy | 14 21.54 | 0 0.00 | 14 43.75 | 0 0.00 | 0 0.00 |
| HFNC | 8 12.31 | 0 0.00 | 0 0.00 | 8 100.00 | 0 0.00 |
| NIPPV | 12 18.46 | 0 0.00 | 0 0.00 | 0 0.00 | 12 80.00 |
| IPPV | 3 4.62 | 0 0.00 | 0 0.00 | 0 0.00 | 3 20.00 |
| CRRT | 3 4.62 | 0 0.00 | 0 0.00 | 0 0.00 | 3 20.00 |
| Glucocorticoids | 31 47.69 | 0 0.00 | 10 31.25 | 8 100.00 | 13 86.67 |
| Prognosis | N | N | N | N | N |
| Remained in hospital | 0 0.00 | 0 0.00 | 0 0.00 | 0 0.00 | 0 0.00 |
| Discharged | 63 96.92 | 10 100.00 | 32 100.00 | 8 100.00 | 15 86.67 |
| Died | 2 3.08 | 0 0.00 | 0 0.00 | 0 0.00 | 2 13.33 |
| Med IQR Med IQR Med IQR Med IQR Med IQR |
| Onset of symptom to laboratory confirmed, days | 5 3–7 | 3 1–9 | 4 2.5–6 | 5.5 2.5–9 | 7 4–14 |
| Onset of symptom to pneumonia, days | 6 3–8 | 4 4–9 | 5.5 2–7.5 | 5 2.5–7 | 7 5–11 |
| Onset of symptom to virus RNA clearance, days | 15 11–20 | 6 4–12 | 14.5 11.5–18.5 | 18 13–22 | 20 16–26 |
| Methylprednisolone time (n = 31) | 7 5–9 | 5 4–9 | 7.5 4–9 | 7.5 5–10.5 | 8 6.5–10 |
| Onset of symptom to discharge, days (n = 63) | 27 17–34 | 13 9–18 | 24.5 16–32 | 35 31–44.5 | 34 28–41 |
All medical records were reviewed by a trained team of physicians. Information included demographics, exposure history, concurrent diseases, symptoms, laboratory results, chest X-ray and/or computed tomographic (CT) images, treatment (ie, antiviral therapy, corticosteroids use, respiratory support and continuous renal replacement therapy [CRRT]). Laboratory data included blood routine, biochemistry (ie, liver, kidney and cardiac function, electrolyte, creatine kinase [CK]), coagulation function, infection related biomarkers (ie, C-reactive protein [CRP], procalcitonin [PCT], Interleukin-6 [IL-6], erythrocyte sedimentation rate [ESR], serum ferritin) and lymphocyte subgroup. Acute respiratory distress syndrome (ARDS) was defined according to the Berlin definition\(^2\). Acute kidney injury (AKI) was identified according to the Kidney Disease: Improving Global Outcomes definition\(^3\).

Clinical types of COVID-19 included mild, general, severe, and critical types. Mild type was diagnosed as patients with mild clinical symptoms and no pneumonia on radiological imaging. General type was diagnosed as patients with fever, respiratory symptoms, and pneumonia on imaging. Severe type was diagnosed as patients with any one of the following: 1. Respiratory distress, RR (Respiratory rates) ≥ 30 bpm; 2. Peripheral capillary oxygen saturation (SpO₂) at rest ≤ 93%. 3. Arterial oxygen partial pressure (PaO₂)/fraction of inspiration O₂ (FiO₂) ≤ 300 mmHg. (1 mmHg = 0.133 kPa). Critical type was diagnosed as patients with any one of the following: 1. Respiratory failure and mechanical ventilation required. 2. Shock. 3. Combined with other organ failures and ICU monitoring and treatment needed\(^1\).

All methods in this study were performed in accordance with the Diagnosis and Treatment of Pneumonia caused by Novel Coronavirus (Version 6 Trial) published on the website of the Central Government of the People's Republic of China\(^1\). This study was approved by the ethics committee of Fifth Medical Center of PLA General Hospital. Written informed consent was waived by the ethics committee of Fifth Medical Center of PLA General Hospital in light of the urgent need to collect clinical data.

**Statistical analysis.** Continuous variables were described as mean ± standard deviation (SD) or medians (interquartile range [IQR] values) as appropriate. Categorical variables were summarized as the counts and percentages in each category. Comparisons between different clinical types were conducted using ANOVA for continuous variables when homogeneity of variance is valid, or else using Wilcoxon rank-sum test. Chi-square test was used for categorical variables when homogeneity of variance is valid, or else using Fisher's exact test. IL-6 values and T lymphocyte counts were tested every 2–3 days. A linear mixed model was built to describe the relationship between clinical type or corticosteroids used and these dynamic IL-6 values or T lymphocyte counts throughout the course of the disease. All analysis used a two-sided \(P\) value of 0.05 for statistical significance. Statistical analyses were performed using SAS 9.4 (SAS Institute Inc. Cary. NC. USA).

**Ethical approval and informed consent.** This study was approved by the ethics committee of Fifth Medical Center of PLA General Hospital. Written informed consent was waived in light of the urgent need to collect clinical data.

**Results**

**Demographic and clinical characteristics.** Details of demographic and clinical characteristics are shown in Table 1. A total of 65 patients were included in our study with 10 (15.38%) mild, 32 (49.23%) general, 8 (12.31%) severe, and 15 (23.08%) critical type. The mean (SD) age was 48.4 (18.46) years and 55.38% of them were male. Three patients (4.62%) were under 15 years old (the youngest one was 3 years old), and 15 patients (23.08%) were over 65 years old. All 3 younger patients (all with mild type) had a quick recovery to discharge with median virus RNA clearance time of 4 days. Patients with critical type tended to be older than those with mild type \(P < 0.0001\). There was no significant difference by gender among different clinical types \(P = 1.000\).

A history of recent travel to or living in Wuhan, contact with people confirmed with COVID-19, and contact with people from Wuhan were documented in 55.38%, 26.15% and 7.69% of patients, respectively. Not all patients could provide their exact exposure time. There were 49 patients with complete exposure time information. The range of time from exposure to onset of symptoms (incubation period) was 0 to 21 days, with median (IQR) of 6 (4–10) days. Notably, 2 patients presented at 14 days, 1 patient at 16 days and 1 patient at 21 days.

Twenty-two patients (33.85%) had at least one concurrent disease (i.e. hypertension, diabetes, malignancy, endocrine disease, and tumor). Patients with any concurrent disease were significantly more likely to be diagnosed as critical cases (60% with any concurrent disease) as compared to other patients (mild 10%, general 25%, and severe 50%) \(P = 0.0264\).

Fever (86.15%) and dry cough (56.92%) were the most common symptoms. The mean (SD) maximum temperature was 38.04 (0.86) °C. There was no significant difference in fever and dry cough among patients with different clinical types \((P > 0.05)\). The median (IQR) times of onset of symptom to laboratory confirmation and pneumonia were 5 (3–7) and 6 (3–8) days, respectively. The median (IQR) time of onset of symptom to virus RNA clearance was 15 (11–20) days. Virus RNA clearance time lengthened with disease progression \((P = 0.0001)\). The most common pattern on chest X-ray and CT in patients with pneumonia was bilateral patchy shadowing and bilateral ground-glass opacity, respectively.

**Laboratory parameters of patients in different clinical types.** Details of laboratory results are shown in Table 2, Supplemental Tables S1 and S2. Laboratory abnormalities, including aspartate amino transferase (ALT), CK, potassium, creatine kinase-MB (CKMB), myocardial troponin I (cTnI), myoglobin, N-terminal pro-brain natriuretic peptide (NT-pro BNP), and lactate (LAC), were more common as disease worsened \((P < 0.05)\). Nineteen (29.23%) patients had lymphopenia (lymphocyte count < 1.0 × 10⁹/L). No mild type patients had lymphopenia, however, 73.33% of critical type did \((P < 0.0001)\). In lymphocyte subgroup analysis,
Counts of infection-related biomarkers were significantly higher in critical patients (80%, 80%, 73.33%, and 73.33%, respectively) than in mild patients (10%, 10%, 10%, and 20%, respectively). Increases in all four infection-related biomarkers above were observed more often throughout the course of the disease are shown in Fig. 1b.

Linear mixed models showed the relationship between clinical type and dynamic IL-6 values or T lymphocytes was significant (P = 0.0796) (Table 5). When adjusted for age, gender, concurrent disease, and severity of disease (clinical type), corticosteroids inhibited IL-6 levels significantly (P = 0.0215) (Table 3) but did not affect T lymphocyte counts (P = 0.0796) (Table 5). When adjusted for age, gender, concurrent disease, and corticosteroids use, IL-6 levels fluctuated and then decreased to normal as patients recovered. The fluctuation was probably influenced by corticosteroids use. IL-6 trends in different clinical types throughout the course of the disease are shown in Fig. 1a.

Forty-four (67.69%), 34 (52.31%), 33 (50.77%), and 35 (53.85%) patients had increased IL-6, ESR, serum ferritin, and CRP, respectively. Increases in all four infection-related biomarkers above were observed more often in critical patients (80%, 80%, 73.33%, and 73.33%, respectively) than in mild patients (10%, 10%, 10%, and 20%, respectively) (All P < 0.05). During treatment, the IL-6 levels fluctuated and then decreased to normal as patients recovered. The fluctuation was probably influenced by corticosteroids use.

### Table 2. Infection-related biomarkers and Lymphocyte subgroup of patients with COVID-19 in different clinical types

|               | Mild (n = 10) | General (n = 32) | Severe (n = 8) | Critical (n = 15) | P       |
|---------------|--------------|-----------------|---------------|------------------|---------|
|               | Mean         | SD              | Mean          | SD               | Mean    | SD    |
| Infection-related biomarkers |              |                 |               |                  |         |       |
| IL-6 (pg/ml)  | 5.36         | 1.84            | 13.76         | 9.07             | 15.94   | 14.88 |
| ESR (mm/h)    | 8.75         | 6.66            | 29.38         | 21.76            | 33.38   | 27.32 |
| Serum ferritin (ng/ml) | 148.22 | 196.53          | 396.02        | 260.29           | 469.53  | 188.18 |
| CRP (mg/l)    | 7.79         | 10.88           | 12.79         | 7.70             | 17.84   | 15.09 |
| T lymphocyte  | 1,194.29     | 400.10          | 857.74        | 283.59           | 582.25  | 305.80 |
| CD4 (n/μl)    | 685.71       | 237.23          | 454.16        | 193.24           | 317.63  | 162.30 |
| CD8 (n/μl)    | 475.86       | 159.60          | 385.74        | 142.82           | 237.63  | 168.54 |
| B (n/μl)      | 254.57       | 196.68          | 175.47        | 100.13           | 127.88  | 81.13 |
| NK (n/μl)     | 317.86       | 245.90          | 201.23        | 215.58           | 165.88  | 173.58 |
| Lymphocyte subgroup |          |                 |               |                  |         |       |
| Total (n/μl)  | 1,810.57     | 730.95          | 1,266.27      | 432.62           | 992.5  | 441.84 |
| T (n/μl)      | 1,194.29     | 400.10          | 857.74        | 283.59           | 582.25  | 305.80 |
| CD4 (n/μl)    | 685.71       | 237.23          | 454.16        | 193.24           | 317.63  | 162.30 |
| CD8 (n/μl)    | 475.86       | 159.60          | 385.74        | 142.82           | 237.63  | 168.54 |
| B (n/μl)      | 254.57       | 196.68          | 175.47        | 100.13           | 127.88  | 81.13 |
| NK (n/μl)     | 317.86       | 245.90          | 201.23        | 215.58           | 165.88  | 173.58 |

Details of treatment and clinical outcomes are shown in Table 1. Interferon-α (IFN-α) (59, 90.77%) and lopinavir/ritonavir (50, 76.92%) were the main antivirus medicines used in these patients. Oxygen therapy, high-flow nasal cannula (HFNC), non-invasive positive pressure ventilation (NIPPV), and invasive positive pressure ventilation (IPPV) were applied to 14 (21.54%), 8 (12.31%), 12 (18.46%), and 3 (4.62%) patients, respectively. The median (IQR) time of onset of symptom to HFNC use and mechanical ventilation was 13 (11–19) days and 14.5 (11.5–17) days, respectively. CRRT was applied to 3 critical patients in AKI stage 2.

Methylprednisolone (mPSL) was applied to 31 (47.69%) patients with pneumonia, including 10 (31.25%) general, 8 (100%) severe, and 13 (86.67%) critical patients, respectively. The dosage and duration of mPSL were prescribed individually. In the 31 patients using mPSL, the median (IQR) dosage of mPSL was 1 (1–5) mg/kg day, including 1 (1–2) mg/kg day mPSL in patients with general type, 3 (1–5) mg/kg day mPSL in patients with severe type, and 2 (1–4) mg/kg day mPSL in patients with critical type. We divided patients with mPSL into lower dose (≤ 2 mg/kg day) and higher dose (> 2 mg/kg day) group. The number of patients using lower dose (≤ 2 mg/kg day) and higher dose (> 2 mg/kg day) of mPSL was 20 (64.52%) and 11 (35.48%), respectively.

Thirty of the 31 patients (96.77%) had stopped mPSL due to improvement of pneumonia on chest X-ray/CT or PaO2/FiO2. One patient died of severe ARDS during mPSL use. Another patient died of septic shock after mPSL use had been stopped 11 days. The median (IQR) time of mPSL use was 7 (5–9) days. The side effects of using mPSL in these 31 patients were hypertension (8, 25.81%), hyperglycemia (11, 35.48%), hypokalemia (11, 35.48%), arrhythmia (4, 12.9%), neuropsychiatric symptoms (2, 6.45%), and gastrointestinal bleeding (1, 3.23%). All above side effects were relieved after symptomatic treatment.

The median (IQR) of virus clearance time in patients without mPSL (12.5, 6–17 days) was shorter than in patients with mPSL (19, 14–22 days) (P = 0.0003). But in general type, there was no significant difference in virus clearance time between patients with (15, 12–19 days) and without mPSL use (14.5, 11–18 days) (P = 0.7372).

Linear mixed models showed the relationship between clinical type and dynamic IL-6 values or T lymphocytes as well as the relationship between corticosteroids use and dynamic IL-6 values or T lymphocytes throughout the course of the disease. When adjusted for age, gender, concurrent disease, and severity of disease (clinical type), corticosteroids inhibited IL-6 levels significantly (P = 0.0215) (Table 3) but did not affect T lymphocyte counts (P = 0.0796) (Table 5). When adjusted for age, gender, concurrent disease, and corticosteroids use, IL-6 increased dramatically in patients with severe and critical types compared to patients with mild type (All P < 0.05) (Table 3), whereas T lymphocytes decreased dramatically in patients with severe and critical types compared to patients with mild type (All P < 0.05) (Table 5).
Another two linear mixed models showed the relationship between corticosteroids dosage (lower and higher dosage) and dynamic IL-6 values or T lymphocytes in patients applied with mPSL. When adjusted for age, gender, concurrent disease, and severity of disease (clinical type), there was no significant difference between patients using corticosteroids at lower (≤ 2 mg/kg day) and higher dose (> 2 mg/kg day) (All $P > 0.05$) (Tables 4, 6).

The IL-6 levels in patients using corticosteroids decreased quickly after using corticosteroids. Whereas in patients without corticosteroids use, the decrease of IL-6 levels was later and more gradual as patients recovered. The T lymphocyte count trends had a similar pattern throughout the course of disease in patients with and without corticosteroids use. COVID-19, Corona Virus Disease 2019, IL-6 interleukin-6, mPSL methylprednisolone.

**Figure 1.** Dynamic IL-6 levels and T lymphocyte counts trends of patients with COVID-19 in different group throughout the course of the COVID-19. (a,b) showed the T lymphocyte and IL-6 level trends in different clinical types throughout the course of the disease. T lymphocytes increased gradually as patients recovered. During treatment, the IL-6 levels fluctuated and then decreased to normal as patients recovered. There was no records of dynamic T lymphocytes and IL-6 levels in patients with mild type. (c,d) showed the IL-6 levels and T lymphocyte trends, respectively. The IL-6 levels in patients using corticosteroids decreased quickly after using corticosteroids. Whereas in patients without corticosteroids use, the decrease of IL-6 levels was later and more gradual as patients recovered. The T lymphocyte count trends had a similar pattern throughout the course of disease in patients with and without corticosteroids use. COVID-19, Corona Virus Disease 2019, IL-6 interleukin-6, mPSL methylprednisolone.
Table 3. Linear mixed model for dynamic IL-6 levels with corticosteroids use (with or without) in patients with COVID-19. Adjusted for age, gender, co-occurring diseases.

|                | Estimate | P     |
|----------------|----------|-------|
| Without corticosteroids (n = 34) | Ref |       |
| With corticosteroids (n = 31)     | -9.66   | 0.0215|
| Mild type (n = 10)                | Ref     |       |
| General type (n = 32)             | 7.78    | 0.1247|
| Severe type (n = 8)               | 14.90   | 0.0385|
| Critical type (n = 15)            | 25.35   | 0.0005|
| Mild type (n = 10)                | -7.78   | 0.1247|
| General type (n = 32)             | Ref     |       |
| Severe type (n = 8)               | 7.12    | 0.1574|
| Critical type (n = 15)            | 17.58   | 0.0006|
| Mild type (n = 10)                | -14.90  | 0.0385|
| General type (n = 32)             | -7.12   | 0.1574|
| Severe type (n = 8)               | Ref     |       |
| Critical type (n = 15)            | 10.46   | 0.0195|
| Mild type (n = 10)                | -25.35  | 0.0005|
| General type (n = 32)             | -17.58  | 0.0006|
| Severe type (n = 8)               | -10.46  | 0.0195|
| Critical type (n = 15)            | Ref     |       |

Table 4. Linear mixed model for dynamic IL-6 levels with different corticosteroids dosage (lower and higher dose) in patients with COVID-19. Adjusted for age, gender, co-occurring diseases, clinical type.

|                | Estimate | P     |
|----------------|----------|-------|
| ≤ 2 mg/kg day (lower dose) (n = 20) | Ref |       |
| > 2 mg/kg day (higher dose) (n = 11)    | -2.33   | 0.5856|

Table 5. Linear mixed model for dynamic T lymphocytes with corticosteroids use (with or without) in patients with COVID-19. Adjusted for age, gender, co-occurring diseases.

|                | Estimate | P     |
|----------------|----------|-------|
| Without corticosteroids (n = 34) | Ref |       |
| With corticosteroids (n = 31)     | -190.82  | 0.0796|
| Mild type (n = 10)                | Ref     |       |
| General type (n = 32)             | -310.12 | 0.06  |
| Severe type (n = 8)               | -450.45 | 0.0343|
| Critical type (n = 15)            | -672.74 | 0.0009|
| Mild type (n = 10)                | 310.12  | 0.06  |
| General type (n = 32)             | Ref     |       |
| Severe type (n = 8)               | -140.33 | 0.3011|
| Critical type (n = 15)            | -362.63 | 0.0025|
| Mild type (n = 10)                | 450.45  | 0.0343|
| General type (n = 32)             | 140.33  | 0.3011|
| Severe type (n = 8)               | Ref     |       |
| Critical type (n = 15)            | -222.30 | 0.0982|
| Mild type (n = 10)                | 672.74  | 0.0009|
| General type (n = 32)             | 362.63  | 0.0025|
| Severe type (n = 8)               | 222.30  | 0.0982|
| Critical type (n = 15)            | Ref     |       |
antibody that acts as an IL-6 receptor antagonist, specifically binding to soluble or membrane-type IL-6 receptors. Several studies have shown very good effects of tocilizumab in patients with COVID-19\(^3\)\(^6\),\(^3\)\(^7\). Meanwhile, a fatal outcome in COVID-19\(^1\)\(^2\)\(^\ast\)\(^1\)\(^2\)\(^\ast\)\(^2\). In order to decrease the cytokine storm, aside from corticosteroids, Tocilizumab heptoxicity drugs\(^3\)\(^7\). Some studies also found its rare but possible serious hepatotoxicity, especially when used together with other 

\[ \text{kg day} \] and higher dose (\(> 2 \text{ mg/kg day} \)) mPSL. Therefore, application of lower dose corticosteroids (\(\leq 2 \text{ mg/kg day} \)) could inhibit IL-6 production (a representative of cytokines) as effectively as a higher dose.

| Estimate | \(P\) |
|----------|-------|
| \(\leq 2 \text{ mg/kg day} \) (Lower dose) (n = 20) | Ref |
| \(> 2 \text{ mg/kg day} \) (Higher dose) (n = 11) | 136.56 | 0.244 |

**Table 6.** Linear mixed model for dynamic T lymphocytes with different corticosteroids dosage (lower and higher dose) in patients with COVID-19. Adjusted for age, gender, cocurrent diseases, clinical type.

Fever, dry cough and bilateral patchy shadowing on chest X-ray were the most common clinical features, whereas other symptoms (ie. myalgia, fatigue, dyspnea, anorexia, diarrhea, nausea and vomiting) were observed in less than 35% of cases. Chest CT feature was more typical with bilateral ground-glass opacity. The duration of time from onset of symptoms to pneumonia was similar in different clinical types. However, the onset of symptom to virus RNA clearance time lengthened dramatically as clinical type worsened.

The laboratory abnormalities observed in this study were leucopenia, lymphopenia, elevated D-dimer, ESR, IL-6, serum ferritin, CRP, and LAC, which were related to sustained inflammatory response. All the observed abnormalities were more pronounced in critical patients than in mild ones. We also observed that COVID-19 is more severe in older people as well as patients with concurrent diseases as these patients generally had weaker immune functions\(^3\)\(^6\),\(^3\)\(^7\). Decreased T, CD4, and CD8 lymphocytes were much more common in critical patients than in mild ones in our study. A substantial decrease in total number of lymphocytes indicates that coronavirus consumes many immune cells and inhibits the body’s cellular immune function. Damage to T lymphocytes might be an important factor leading to exacerbations of patients\(^2\)\(^9\). All the evidence indicates that COVID-19 might mainly act on lymphocytes, especially T lymphocytes. In this study, decreased lymphocytes, including total, T, CD4, and CD8 lymphocytes, were more common as the disease worsened.

The SARS-CoV-2 could activate the immune system and induce a pro-inflammatory cascade\(^3\)\(^2\). IL-6 plays an important role in COVID-19-induced cytokine storm, characterized by an extreme auto-amplifying cytokine reaction which is followed by infiltration of inflammatory monocytes/macrophages and lymphocytes into the lung\(^2\)\(^7\). In treatment of SARS-CoV\(^1\)\(^3\),\(^1\)\(^4\) and MERS-CoV\(^1\)\(^5\), corticosteroids were commonly used to treat patients with severe illness by reducing lung inflammatory. Some reports did not support corticosteroid treatment, because it could inhibit immune responses and virus clearance\(^2\)\(^8\),\(^2\)\(^9\),\(^3\)\(^0\). However, some studies supported the use of corticosteroids in patients with coronavirus infection because it could reduce mortality and the need for mechanical ventilation, and shorten the length of stay in hospital\(^3\)\(^1\),\(^3\)\(^2\),\(^3\)\(^3\). In COVID-19 treatment, the mPSL was applied according to the Chinese COVID-19 corticosteroids use recommendation\(^1\)\(^1\),\(^1\)\(^8\), severity of pneumonia, the progress of inflammation, and the patients’ response to mPSL. Therefore the dosage and duration were individually.

In this study, mPSL was applied to 47.69% of patients with COVID-19, including 31.25% general, 100% severe, and 86.67% critical patients, respectively. Thirty of the 31 patients (96.77%) with mPSL using had stopped mPSL due to improvement of pneumonia. We found that corticosteroids inhibited IL-6 production because it could reduce mortality and the need for mechanical ventilation, and shorten the length of stay in hospital. In COVID-19 treatment, the mPSL was applied according to the Chinese COVID-19 corticosteroids use recommendation\(^1\)\(^1\),\(^1\)\(^8\), severity of pneumonia, the progress of inflammation, and the patients’ response to mPSL. Therefore the dosage and duration were individually.

Some studies reported that mPSL may delay virus clearance time\(^3\)\(^7\),\(^3\)\(^4\). In our study, all severe and most critical patients used mPSL. We could not distinguish whether the lengthened virus RNA clearance time was completely due to disease progression or if it was impacted by mPSL use. We could not compare the virus clearance time of using versus not using mPSL in severe and critical groups due to almost all of these patients being treated with mPSL. In general type, 31.25% of patients used mPSL and 68.75% of patients didn't use, and the virus clearance time was similar between users and non-users. Therefore, more study is necessary to elucidate whether properly using corticosteroids delays virus clearance time among patients with COVID-19.

Proper use of corticosteroids could have led to the improvement observed in this study. The following rules should be considered when using corticosteroids: 1. When to start and stop using corticosteroids should be carefully weighed. 2. Dosage should be personalized, and the duration should be short, especially in critical patients. 3. Side effects should be seriously monitored and promptly addressed.

IL-6 plays an important role in COVID-19-induced cytokine storm\(^2\)\(^7\). Elevated levels of IL-6 are predictive of a fatal outcome in COVID-19\(^1\)\(^9\). In order to decrease the cytokine storm, aside from corticosteroids, Tocilizumab (TCZ) has been proposed to treat severe forms of COVID-19\(^2\)\(^7\). TCZ is a humanized recombinant monoclonal antibody that acts as an IL-6 receptor antagonist, specifically binding to soluble or membrane-type IL-6 receptors. Several studies have shown very good effects of tocilizumab in patients with COVID-19\(^9\)\(^6\),\(^3\)\(^7\). Meanwhile, some studies also found its rare but possible serious hepatotoxicity, especially when used together with other hepatotoxic drugs\(^3\)\(^7\).

This study has several limitations. Only 65 patients with confirmed COVID-19 in Beijing were included, thus certain subgroup analyses had limited statistical power, such as treatment effect comparison and mortality. We will continue to collect multi-center cases in order to have a more comprehensive understanding of COVID-19.
Conclusion
The incubation period of COVID-19 in a few patients is likely to be greater than 14 days. Lymphocyte, especially T lymphocyte, in severe and critical patients showed a dramatic decrease. Application of lower dose corticosteroids (≤2 mg/kg day) could inhibit IL-6 production (a representative of cytokines) as effectively as a higher dose. Proper use of corticosteroids in general type patients did not delay virus clearance. For patients with moderate to severe ARDS, timely use of mechanical ventilation and CRRT guarantees a better prognosis.

References
1. Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet https://doi.org/10.1016/S0140-6736(20)30183-5 (2020).
2. Wang, D. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA https://doi.org/10.1001/jama.2020.1585 (2020).
3. WHO Director-General's Remarks at the Media Briefing on 2019-nCoV on 11 February 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-n cov-on-11-february-2020. Accessed 11 Feb 2020.
4. World Health Organization (WHO). Coronavirus Disease 2019-Situation Reports. (Accessed 15 April 2020); https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/.
5. Chan, J. F. A. et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster. Lancet https://doi.org/10.1016/S0140-6736(20)30154-9 (2020).
6. Phan, L. T. et al. Importation and human-to-human transmission of a novel coronavirus in Vietnam. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2001272 (2020).
7. Rothe, C. et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2001468 (2020).
8. Wu, J. T., Leung, K. & Leung, G. M. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: A modelling study. Lancet https://doi.org/10.1016/S0140-6736(20)30260-9 (2020).
9. Li, Q. et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2001316 (2020).
10. National Health Commission of the People's Republic of China. (Accessed 15 April 2020); https://www.nhc.gov.cn/.
11. Diagnosis and Treatment of Pneumonia caused by Novel Coronavirus Published on Central Government of the People's Republic of China Website. (Accessed 15 April 2020); https://www.gov.cn/zhengce/zhengceku/2020-02/19/content_5480948.htm.
12. Zhao, M. Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies. Int. J. Antimicrob. Agents https://doi.org/10.1016/1001-0939(20)30592-9 (2020).
13. Wong, C. K. et al. Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: Relation to the acute lung injury and pathogenesis of SARS. J. Pathol. 210, 288–297. https://doi.org/10.1002/path.2067 (2006).
14. Faure, E. et al. Distinct immune response in two MERS-CoV-infected patients: Can we go from bench to bedside? PLoS ONE 9, e88716. https://doi.org/10.1371/journal.pone.0088716 (2014).
15. Stockman, L. J., Bellamy, R. & Garner, P. SARS: Systematic review of treatment effects. PLoS Med. 3, e343. https://doi.org/10.1371/journal.pmed.0030333 (2006).
16. Arabi, Y. M. et al. Corticosteroid therapy for critically ill patients with middle east respiratory syndrome. Am. J. Respir. Crit. Care Med. 197, 757–767. https://doi.org/10.1164/rccm.201706-1172OC (2018).
17. Zhao, J. P. et al. Expert consensus on the use of corticosteroids in patients with 2019-nCoV pneumonia. Zhonghua J He He Hu Xi Za Zhi 43, 183–184. https://doi.org/10.3760/cma.j.issn.1001-0939.2020.03.008 (2020).
18. Shang, L., Zhao, J., Hu, Y., Du, R. & Cao, R. On the use of corticosteroids for 2019-nCoV pneumonia. The Lancet 395, 683–684. https://doi.org/10.1016/S0140-6736(20)30361-5 (2020).
19. WHO. Laboratory Testing for 2019-nCoV in Humans. (Accessed 15 April 2020); https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance.
20. Central Government of the People's Republic of China website.
21. Force, A. D. T. et al. Acute respiratory distress syndrome: The Berlin definition. JAMA 307, 2526–2533. https://doi.org/10.1001/jama.2012.5669 (2012).
22. Khwaja, A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin. Pract. 120, c179–184. https://doi.org/10.1159/000339789 (2012).
23. Badawi, A. & Ryyo, S. G. Prevalence of comorbidities in the middle east respiratory syndrome coronavirus (MERS-CoV): A systematic review and meta-analysis. Int. J. Infect. Dis. 49, 129–133. https://doi.org/10.1016/j.ijid.2016.06.015 (2016).
24. Channappanavar, R. et al. Sex-based differences in susceptibility to severe acute respiratory syndrome coronavirus infection. J. Immunol. 198, 4046–4053. https://doi.org/10.4049/jimmunol.1601896 (2017).
25. Liu, W. J. et al. T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV. Antiviral Res. 137, 82–92. https://doi.org/10.1016/j.antiviral.2016.11.006 (2017).
26. Giamarellos-Bourboulis, E. J. et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe https://doi.org/10.1016/j.chom.2020.04.009 (2020).
27. Peiris, J. S. et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: A prospective study. Lancet 361, 1767–1772. https://doi.org/10.1016/S0140-6736(03)13412-5 (2003).
28. Beijing Group of National Research Project for SARS. Dynamic changes in blood cytokine levels as clinical indicators in severe acute respiratory syndrome. Chin. Med. J. (Engl.) 116, 1283–1287 (2003).
29. Arabi, Y. M. et al. Middle east respiratory syndrome. N. Engl. J. Med. 367, 584–594. https://doi.org/10.1056/NEJMra1408795 (2017).
30. Chen, R. C. et al. Treatment of severe acute respiratory syndrome with glucocorticoids: The Guangzhou experience. Chest 129, 1441–1452. https://doi.org/10.1378/chest.129.6.1441 (2006).
31. Li, H. et al. Effect of low-to-moderate-dose corticosteroids on mortality of hospitalized adolescents and adults with influenza A/H1N1)pdm09 viral pneumonia. Influenza Other Respir. Viruses 11, 345–354. https://doi.org/10.1111/irv.12456 (2017).
32. Siemieniuk, R. A. et al. Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: A systematic review and meta-analysis. Ann. Intern. Med. 163, 519–528. https://doi.org/10.7326/M15-0715 (2015).
33. Lee, N. et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J. Clin. Virol. 31, 304–309. https://doi.org/10.1016/j.jcv.2004.07.006 (2004).
34. Howell, M. D. & Davis, A. M. Management of ARDS in adults. JAMA 319, 711–712. https://doi.org/10.1001/jama.2018.0307 (2018).
36. Xu, X. et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc. Natl. Acad. Sci. U.S.A. 117, 10970–10975. https://doi.org/10.1073/pnas.2005615117 (2020).

37. Muhović, D. et al. First case of drug-induced liver injury (DILI) associated with the use of tocilizumab in a patient with COVID-19. Liver Int. https://doi.org/10.1111/liv.14516 (2020).

Acknowledgements
Biosecurity Construction Plan (A3704041901-09).

Author contributions
J.M. and F.L. had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. F.L. and C.J. contributed equally and share first authorship. Literature search: F.L., J.M. and H.H. Figures: WW. and F.L. Study design: J.M. and F.L. Data collection: F.L., Y.S. and S.J. Data analysis: F.L., J.L. and WW. Data interpretation: F.L., J.M., Y.Z., E.Q. and T.J. Medical staff for patients’ management: J.M., G.M., X.H., C.J., J.Z., Z.Z., E.Q., T.J., F.L. and Y.W. Writing: F.L., Y.Z. and S.L.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-70387-2.

Correspondence and requests for materials should be addressed to Y.Z., E.Q. or J.M.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020